Authors

Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen

Phase 3 ARASENS trial results highlight the role of G-CSF in optimizing docetaxel delivery within the darolutamide-based regimen for mHSPC.

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.

64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative

44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)

15 Technique of Surgeon-Performed Intraoperative Regional Pectoral Nerve Block for Patients Undergoing Mastectomy

Intraoperative surgeon-performed PECs block during mastectomy resulted in only 16.6% of patients requiring postoperative opioids, supporting this technique as a fast and effective method of regional analgesia.

Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma

Experts gathered to discuss various facets of early-relapse multiple myeloma treatment, such as exposure vs refractoriness and CAR T vs bispecifics.

14 Advancing Breast Cancer Diagnosis in Rural Kenya: Bridging Histopathological Gaps Toward Global Breast Cancer Initiative (GBCI) Goals

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

Sound Tools May Reduce Anxiety in Gynecologic Oncology Settings

Sound machines may represent a high-yield, low-effort intervention for improving patient experiences in gynecologic oncology clinics.

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer

Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.

40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study

In a retrospective multi-institution study of 267 early-stage breast cancer patients, the TumorSight Viz AI algorithm achieved landmark identification and measurement accuracy comparable to inter-radiologist variability, generating results in an average of 8 minutes per patient.

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

48 Validation of a Multi-omic Biosignature to Predict Locoregional Recurrence Risk and the Benefit of Adjuvant Radiation Therapy in Women With Early-Stage Invasive Breast Cancer Treated With Breast-Conserving Surgery and Endocrine Therapy

In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.

Top 3 Insights on Locoregional Recurrence in Young-Onset Breast Cancer

New findings presented at the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.

43 MP2—The Next-Generation MarginProbe Device: Incremental Performance Gains in an Area of Persistent Unmet Need

In this prospective multicenter study, the next-generation MarginProbe device (MP2) achieved sensitivity of 76.8% and specificity of 49.1% for intraoperative lumpectomy margin assessment, meeting all predefined success criteria and earning FDA approval in September 2025.

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

Current Treatment of Peripheral T-cell Lymphoma

This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.

41 A Case Series of Sarcomas